63 results
8-K
EX-99.1
BCDA
BioCardia Inc.
19 Dec 23
Other Events
7:00am
patients treated with culture expanded MSCs or dedicated controls using the Helix delivery system with no observed treatment emergent serious adverse events
424B5
BCDA
BioCardia Inc.
17 Nov 23
Prospectus supplement for primary offering
5:25pm
Our second therapeutic platform is our investigational culture expanded bone marrow derived allogenic or "off the shelf" mesenchymal cell therapy
8-K
EX-99.1
BCDA
BioCardia Inc.
9 Aug 23
Biocardia Reports Second Quarter 2023 Business Highlights and Financial Results
4:08pm
) in ischemic heart failure using the Company’s proprietary Helix™ delivery system encompassing 93 patients treated with culture expanded MSCs
424B5
a6l eyobwc
22 Jun 23
Prospectus supplement for primary offering
8:33am
8-K
EX-99.1
2oetlolhlngu10nu
6 Dec 22
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
7:01am
8-K
EX-99.1
g1s833zaf81qkut
9 Nov 22
Biocardia Reports Third Quarter 2022 Business Highlights and Financial Results
4:07pm
8-K
EX-99.1
g2mh7aihkte
10 Aug 22
Biocardia Reports Second Quarter 2022 Business Highlights and Financial Results
4:06pm
8-K
EX-99.1
fipsdyoqbtc8
11 May 22
Biocardia Reports First Quarter 2022 Business Highlights and Financial Results
4:06pm
424B5
9txkd2
12 Apr 22
Prospectus supplement for primary offering
8:01am
8-K
EX-99.1
yntxpnr63p4ttmjgv0wu
29 Mar 22
Biocardia Reports 2021 Financial Results and Recent Business Highlights
4:07pm